Trial Profile
An Open Label, Dose Escalation Phase I Study to Evaluate the Safety and Tolerability of Continuous Twice-daily Oral Treatment of Nintedanib in Japanese Patients With Hepatocellular Carcinoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 09 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 11 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 05 Nov 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.